The present invention relates to a technique for effective intranasal delivery to the brain. More specifically, the present invention is used for diagnosing, preventing or treating central nervous system encephalopathy, neurodegenerative diseases or brain tumor by effectively delivering to the brain a pH-responsive and bioreducible PPA polymer, which can be used as a drug carrier, by means of nasal administration.

The present invention relates to lipid nanoparticles (LNP) or compositions thereof for delivery of mRNA molecules encoding CAR, nucleic acid molecule, and/or therapeutic agents to selected targets, such as cells. Thus, in various aspects, the present invention also provides methods of preventing or treating diseases or disorders in a subject in need thereof using the said LNPs or compositions thereof.

The present invention relates to lipid nanoparticles (LNP) or compositions thereof for delivery of mRNA molecules encoding CAR, nucleic acid molecule, and/or therapeutic agents to selected targets, such as cells. Thus, in various aspects, the present invention also provides methods of preventing or treating diseases or disorders in a subject in need thereof using the said LNPs or compositions thereof.

The disclosure pertains to the field of molecular means capable of binding to, and preferably of chelating, cGMP, appropriate for use in vitro or in vivo and preferably capable of targeting specific cellular compartments. The polypeptides of the disclosure comprise a chimeric construction derived from the N terminus part of PKG-Iα and PKG-Iβ, and the two cGMP binding sites of the wild type PKG.

The disclosure pertains to the field of molecular means capable of binding to, and preferably of chelating, cGMP, appropriate for use in vitro or in vivo and preferably capable of targeting specific cellular compartments. The polypeptides of the disclosure comprise a chimeric construction derived from the N terminus part of PKG-Iα and PKG-Iβ, and the two cGMP binding sites of the wild type PKG.

An H7 avian influenza vaccine strain which differentiates infected from vaccinated animals, a preparation method therefor, and an application. The highly pathogenic H7 avian influenza not only brings about huge economic losses to the livestock industry, but also seriously threatens public health safety. Conventional H7 avian influenza whole virus inactivated vaccines do have advantages such as being reliable in terms of effect, low in terms of cost and wide in terms of application range, but cannot serologically differentiate infected from vaccinated animals. The present invention uses NA of influenza B as a label to establish a method for constructing an H7 avian influenza vaccine strain which differentiates infection from vaccination, and may be used for the prevention, control and decontamination of the H7 avian influenza.

An H7 avian influenza vaccine strain which differentiates infected from vaccinated animals, a preparation method therefor, and an application. The highly pathogenic H7 avian influenza not only brings about huge economic losses to the livestock industry, but also seriously threatens public health safety. Conventional H7 avian influenza whole virus inactivated vaccines do have advantages such as being reliable in terms of effect, low in terms of cost and wide in terms of application range, but cannot serologically differentiate infected from vaccinated animals. The present invention uses NA of influenza B as a label to establish a method for constructing an H7 avian influenza vaccine strain which differentiates infection from vaccination, and may be used for the prevention, control and decontamination of the H7 avian influenza.

Provided are a microfluidic apparatus, a method and system for introducing a substance into a cell. The microfluidic apparatus includes a cavity channel, a bulk wave generating device and a surface acoustic wave generating device; a microstructure is arranged on an inner wall of the cavity channel, and the microstructure is constructed for forming a bubble by a solution at the microstructure when the solution is injected into the cavity channel; the bulk wave generating device is configured to generate a bulk wave, the bulk wave enables the bubble to resonate for generating a flow field; and the surface acoustic wave generating device is configured to generate a surface acoustic wave and control a position of at least one particle in the solution.

The present application relates to a metal-nucleic acid nanoparticle which is a nanoparticle having a spherical structure formed by assembly of metal ions with nucleic acids via coordination. The preparation thereof is mixing a metal ion solution with a nucleic acid solution to obtain a mixture followed by vortex, heating, centrifugation, washing with water and resuspension to obtain the metal-nucleic acid nanoparticles.

The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide.